Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B

Area of Science:

• Hepatology
• Gastroenterology
• Metabolic Diseases

Background:

• Fatty liver disease and chronic hepatitis B (CHB) are leading causes of chronic liver disease.
• Hepatic steatosis inversely correlates with hepatitis B virus (HBV) activity, but its impact on advanced fibrosis and hepatocellular carcinoma (HCC) is unclear.
• Metabolic dysfunction-associated fatty liver disease (MAFLD) criteria aid diagnosis, but its clinical significance in CHB patients is understudied.

Purpose of the Study:

• To summarize and discuss the clinical impact of MAFLD on CHB patients.
• To investigate the effects of concurrent MAFLD on the prognosis of CHB, including fibrosis and HCC development.
• To highlight the need for comprehensive research on MAFLD in the CHB population.

Main Methods:

• Literature review and synthesis of existing studies.
• Analysis of the relationship between hepatic steatosis, HBV activity, and clinical outcomes.
• Discussion of the implications of MAFLD criteria in CHB management.

Main Results:

• Concurrent hepatic steatosis shows an inverse correlation with HBV activity.
• The effects of MAFLD on advanced fibrosis and HCC development in CHB patients are diverse and inconclusive.
• The clinical impact of MAFLD on CHB prognosis requires further comprehensive investigation.

Conclusions:

• MAFLD criteria offer a new perspective for managing CHB patients with metabolic dysfunction.
• Further research is crucial to understand and improve the clinical management of CHB patients with concurrent MAFLD.
• Clarifying the interplay between MAFLD and CHB is essential for improving patient outcomes and reducing liver disease progression.